{
  "id": 12167343,
  "title": "Shionogi to pay $2B for IntraBio, a commercial rare disease biotech",
  "url": "https://urgent.news/2026/10/05/shionogi-to-pay-2b-for-intrabio-a-commercial-rare-disease-biotech",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T14:19:13.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/shionogi-to-pay-2b-for-intrabio-a-commercial-rare-disease-biotech/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Shionogi is buying an Austin, TX-based commercial biotech for $2 billion upfront, adding another medicine to the Japanese pharma's rare disease portfolio. The drugmaker is scooping up IntraBio and its oral treatment Aqneursa, Shionogi",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}